Open AccessAssociation of the Q141K polymorphism of the ABCG2 gene with the effectiveness of urate-lowering therapy in patients with gout (a pilot study)
Author(s) -
М. С. Елисеев,
М. Н. Чикина,
И А Гусева,
O. V. Zhelyabina,
Е. Ю. Самаркина,
Н. В. Коновалова,
Д. А. Варламов
Publication year - 2021
Publication title -
sovremennaâ revmatologiâ
Language(s) - English
Resource type - Journals
eISSN - 2310-158X
pISSN - 1996-7012
DOI - 10.14412/1996-7012-2021-6-55-60
Subject(s) - gout , allopurinol , febuxostat , medicine , uric acid , gastroenterology , benzbromarone , hyperuricemia , creatinine , gene polymorphism , genotype , urology , surgery , chemistry , gene , biochemistry
Achieving the target serum uric acid (UA) level is a priority in the treatment of gout. Objective : to study the relationship of the ABCG2 gene polymorphism (rs2231142) with the efficacy of allopurinol and febuxostat in patients with gout. Patients and methods . The study included 82 patients with gout over 18 years of age with serum UA level >360 μmol/L who did not take uratelowering therapy. All patients were prescribed allopurinol 100 mg daily, followed by its titration until the target UA level was reached ( A polymorphism (rs2231142) of the ABCG2 gene. We compared the probability of achieving the target UA level, the mean values of a decrease in the serum UA level, and the mean doses of urate-lowering drugs in patients with different genotypes (CC, CA, AA) of the ABCG2 gene. Results and discussion . The target UA level in 45 (55%) of 82 patients was defined as A polymorphism of the ABCG2 gene, but the presence of CA and AA genotypes is identified with a higher dose of the drug. The C>A (rs2231142) polymorphism of the ABCG2 gene does not affect the ability to achieve the goal of therapy when using febuxostat in patients with allopurinol ineffectiveness.